Inhibition of CREBBP/EP300 BRDs leads to a significant reduction in H3K18ac and H3K27ac at the IRF4 super-enhancer and transcription start site, which directly inhibits IRF4 and its downstream target genes such as cMYC, resulting in decreased viability of MM cell lines and causing cell cycle arrest and apoptosis (Figure 4). The gene discussed is EP300; the disease is Miyoshi myopathy.